Analysts Set Hyperion DeFi, Inc. (NASDAQ:HYPD) Target Price at $2.00

Shares of Hyperion DeFi, Inc. (NASDAQ:HYPD) have received an average recommendation of “Reduce” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $2.00.

A number of equities analysts have recently issued reports on HYPD shares. Wall Street Zen downgraded Hyperion DeFi from a “hold” rating to a “sell” rating in a research note on Saturday, July 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperion DeFi in a report on Wednesday, October 8th.

Institutional Investors Weigh In On Hyperion DeFi

An institutional investor recently bought a new position in Hyperion DeFi stock. Virtu Financial LLC purchased a new position in Hyperion DeFi, Inc. (NASDAQ:HYPD) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 23,065 shares of the company’s stock, valued at approximately $25,000. Virtu Financial LLC owned 0.82% of Hyperion DeFi as of its most recent filing with the Securities and Exchange Commission (SEC). 25.84% of the stock is owned by hedge funds and other institutional investors.

Hyperion DeFi Stock Down 8.5%

NASDAQ HYPD opened at $6.60 on Tuesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.91 and a quick ratio of 0.91. Hyperion DeFi has a 1 year low of $0.85 and a 1 year high of $43.63. The business’s 50-day moving average is $8.65 and its 200 day moving average is $6.73. The stock has a market capitalization of $45.94 million, a PE ratio of -0.27 and a beta of 2.57.

Hyperion DeFi (NASDAQ:HYPD) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($2.50) EPS for the quarter. Hyperion DeFi had a negative return on equity of 876.25% and a negative net margin of 62,238.41%. Sell-side analysts forecast that Hyperion DeFi will post -41.6 earnings per share for the current year.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.